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OBJECTIVE The aim of this study was to evaluate the potential of paclitaxel to prevent restenosis in vivo.
BACKGROUND Paclitaxel (Taxol) is a microtubule-stabilizing compound with potent antitumor activity. It
influences the cytoskeleton equilibrium by increasing the assembly of altered microtubules,
thereby inducing cellular modifications that result in reduced proliferation, migration and
signal transduction.
METHODS Before the in vivo study, delivery efficiency was determined with radiolabeled paclitaxel in
porcine hearts. After induction of a defined plaque in the right carotid arteries of 76 New
Zealand rabbits by electrical stimulation, 27 animals underwent balloon dilation and
subsequent local paclitaxel delivery (10 ml, 10 mmol/liter) with a double-balloon catheter.
Twenty-nine animals served as control with angioplasty only, 10 animals underwent local
delivery of vehicle only (0.9% NaCl solution) and 10 animals were solely electrostimulated.
Vessels were excised one, four, and eight weeks after intervention.
RESULTS The extent of stenosis in paclitaxel-treated animals was significantly reduced compared with
balloon-dilated control animals (p 5 0.0012, one, four and eight weeks after intervention:
14.6%, 24.6% and 20.5%, vs. 24.9%, 33.8% and 43.1%, respectively). Marked vessel
enlargement compared with balloon-dilated control animals could be observed (p 5 0.0001,
total vessel area after one, four and eight weeks: paclitaxel group: 1.983, 1.700 and 1.602
mm2, control: 1.071, 1.338 and 1.206 mm2, respectively). Tubulin staining and electron
microscopy revealed changes in microtubule assembly, which were limited to the intimal area.
Vasocontractile function after paclitaxel treatment showed major impairment.
CONCLUSIONS Local delivery of paclitaxel resulted in reduced neointimal stenosis and enlargement in vessel
size. Both these effects contribute to a preservation of vessel shape and are likely to be caused
by a structural alteration of the cytoskeleton. (J Am Coll Cardiol 2000;35:1969–76) © 2000
by the American College of Cardiology
The antitumor drug paclitaxel (Taxol) influences the cy-
toskeleton equilibrium by increasing the assembly of altered
and extraordinarily stable microtubules and thereby reduces
many cellular functions like proliferation, migration and
signal transduction (1–3). It is highly lipophilic, which
promotes a rapid cellular uptake, and has a long-lasting
effect in the cell due to the structural alteration of the
cytoskeleton (4,5). As shown previously, paclitaxel exerts
potent and sustained inhibitory effects on smooth muscle
cell (SMC) proliferation and migration in cell culture, even
after single-dose application (6). This makes paclitaxel a
very promising candidate for local drug therapy intended to
address the proliferative and migratory processes involved in
restenosis (6–8). The current study was designed to evalu-
ate the effects of locally delivered paclitaxel in an experi-
mental rabbit angioplasty model.
METHODS
3H-Paclitaxel delivery in porcine hearts. The efficiency of
delivering paclitaxel with a double-balloon catheter was
assessed ex vivo. In six freshly harvested porcine hearts, the
left anterior descending artery (LAD) was canalized and a
mid segment of the artery underwent balloon overstretch
injury (12 atm, 20 s). Specific activity of the 3H-labeled
paclitaxel (Amersham International, Cardiff, England) was
6.65 Ci/mmol. A volume of 10 ml 3H-paclitaxel (10
mmol/liter) was then delivered with the double balloon
using an application pressure of 0.1 to 0.5 atm. The
balloon-to-artery ratio was 1.2:1, mean application time was
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7.2 6 1.4 min. After rinsing the artery, the vessel segments
and a block of surrounding myocardium were dissected. The
specimens were individually homogenized over night in
1 ml Soluene (Packard, Groningen, the Netherlands) 350 1
0.3 ml H2O2 1 0.3 ml 2-propanol. After the addition of
15 ml Hionic-fluor (Packard), the resulting solution was
transferred to a liquid scintillation counter for determina-
tion of the beta-emitting activity.
Local drug delivery device. A 2.2-mm double-balloon
catheter (Schneider Europe, Bu¨lach, Switzerland) was used
for local drug delivery (LDD). It is an over-the-wire
catheter with a 3-F shaft diameter and a distance between
the two balloons of 20 mm.
Paclitaxel. Paclitaxel (Sigma, Deisenhofen, Germany) was
dissolved in 100% ethanol and filter sterilized. The resulting
stock solution (2.5 mM) was then diluted with sterile 0.9%
NaCl solution to a concentration of 10 mmol/liter.
Animal study. The study protocol was reviewed by the
ethical committee on animal research of our institution and
was found to conform to the guidelines on animal care.
Animals were housed in our facilities for two weeks before
randomization to different treatment groups and inclusion
in the study. During this period, one animal died of acute
hepatitis, which was the only case of death in the whole
study group. As detailed previously (9–11), the electro-
stimulation model was used to induce a fibromuscular
plaque in the right carotid arteries of New Zealand rabbits.
Briefly, this model is based on the implantation of two
graphite-coated gold electrodes in the adventitia of the
common carotid artery. Constant direct current impulses are
then applied twice daily for a stimulation period of 28 days,
and the animals are additionally fed a 0.5% cholesterol diet
(Altromin, Lage, Germany). This combined procedure
leads to an eccentric plaque growing below the anode. After
the induction of eccentric plaque formation in 76 New
Zealand rabbits, balloon dilation (BD) was performed in 66
animals under general anaesthesia (8 mg metomidate-HCL
and 0.1 mg fentanyl base/kg body weight). A 2.0-mm
A.C.S. (Santa Clara, California) Micro-Hartzler balloon
was used for dilation (2 3 30 s, inflation pressure 6 atm). As
control, 29 animals underwent BD only. LDD was per-
formed in 27 animals with the double-balloon catheter and
10 ml of 10 mmol/liter paclitaxel. The double-balloon
catheter was inflated with a pressure of 3 atm, and the drug
was infused with a low pressure (0.1 to 0.5 atm) to allow for
replacement of the escaping drug in the intervention area.
The duration of LDD ranged from 8.6 to 13.1 min, with a
mean of 9.8 min. As sham control group, 10 animals
underwent LDD of vehicle only (0.9% NaCl solution) with
the identical intervention parameters as in the paclitaxel
group. Ten animals were only electrostimulated as a prein-
terventional control group. One, four and eight weeks after
intervention, the animals were killed and the vessels were
excised.
Bromodeoxyuridine (BRDU) labeling and histological
preparation. In order to determine the extent of cells
undergoing DNA synthesis, BRDU, a thymidine analogue,
was given to each animal before the excision of the vessels,
as described earlier (9). Before excision, the arteries were
perfusion fixed in situ. After overnight immersion-fixation,
the excised vessels were cut in five equal segments and
embedded in paraffin. Each vessel segment was serially
sectioned in seven slices of 4 mm each, at intervals of 75 mm.
Each of the seven slices per interval was then stained with
the different stainings as described in the following text. For
quantitative analysis, at least three serial cuts at plaque
maximum were used and then averaged per animal. These
results were then finally averaged for the paclitaxel group
and the three control groups.
Immunocytochemistry and histomorphometry. Immuno-
histological staining of cells with incorporated BRDU was
performed by using a monoclonal antibody against BRDU
(Bio Cell Consulting, Grellingen, Switzerland). Proliferating
cells could be identified as smooth muscle cells (SMCs) with
immunohistological alpha-actin staining (Renner, Dannstadt,
Germany), and macrophages were detected with RAM 11
antibody (12,13). Immunofluorescent tubulin staining was
performed with a monoclonal antibody against alpha-tubulin
(Amersham Buchler, Braunschweig, Germany) that specifi-
cally stains polymerized tubulin (14,15). Controls were done by
performing the identical staining procedure but omitting the
first antibody. Cross sections were additionally stained with a
polyclonal antibody against von Willebrand factor (goat anti-
human factor VIII-related antigen; Atlantic Antibodies, Still-
water, Minnesota). In addition to the immunohistology, his-
tological sections were stained with hematoxylin-eosin and
elastica-van Gieson’s stain. Each staining was performed in
cross sections of each vessel segment. Two independent ob-
servers, blinded to the type of treatment protocol did the
microscopical examination of the histological cross sections.
Elastica-van Gieson’s stained sections were quantitatively an-
alyzed by computerized morphometry using standard software
(Bioquant, Bilaney Consulting, Duesseldorf, Germany). The
area of intima, media and residual lumen was calculated and
the extent of stenosis was determined as follows: % stenosis 5
intimal area 3 100/intimal 1 luminal area.
Transmission electron microscopy. Vessel segments for
electron microscopy were fixed in 2% glutaraldehyde (Pae-
Abbreviations and acronyms
ANOVA 5 analysis of variance
BD 5 balloon dilation
BRDU 5 bromodeoxyuridine
LAD 5 left anterior descending artery
LDD 5 local drug delivery
SMC 5 smooth muscle cell
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sel, Hanau, Germany) in 0.1 mol/liter cacodylate buffer, pH
7.4, for 1 h. The tissue was then washed several times in the
same buffer, postfixed in 1% buffered osmium tetroxide for
1 h, washed again and dehydrated in ethanol. The speci-
mens were then treated with saturated uranyl acetate in 70%
ethanol for 2 h. After the completion of dehydration in
absolute ethanol and propylene oxide, the tissue was em-
bedded in Araldite (Serva, Heidelberg, Germany). Semithin
and ultrathin sections were stained with toluidine blue and
lead citrate, respectively. Ultrathin sections were examined
with EM 10 and EM 902 microscopes (Carl Zeiss, Jena,
Germany) and photographed.
Vascular contractile function. To investigate the effects of
paclitaxel on vascular contractile function, rings of the left,
untreated carotid artery of control animals were removed and
prepared for further analysis. As described elsewhere in detail
(16,17), the rings were then introduced into a contraction
chamber for the measurement of vascular contraction force.
Three different treatment groups were investigated (three
vessel segments/group): 1) rings of carotid artery bathed in
10 mmol/liter paclitaxel for 10 min and investigated immedi-
ately; 2) rings bathed in 10 mmol/liter paclitaxel and then
washed in tyrode for 2 h before measurement and 3) vessel
segments incubated in 10 mmol/liter paclitaxel for 2 h. After
prestretching the vessel rings with 50 mN and subsequent
relaxation for 30 min, contraction was stimulated with isotonic
salt solution in which KCl was increased to 30 mmol/liter, and
contraction force was continuously registered. Using two iden-
tical measuring devices, every paclitaxel-treated vessel ring was
simultaneously investigated with an untreated segment of the
same artery as control.
Statistical evaluation. Results are expressed as mean 6
standard deviation. In order to determine the significance of
differences between paclitaxel-treated animals and balloon-
dilated control animals, a two-way analysis of variance
(ANOVA) was performed for each of the seven variables
considering that the data were obtained at different time
points. This statistical evaluation analyzes all the data for
each variable at once and also reflects the interaction
between therapy and the different time points when the
results were obtained. Because of the additional control
group, a separate one-way ANOVA was formulated for the
results at day 7 after intervention. A complete list of the p
values for the ANOVAs is presented in Table 1; most of the
p values regarding the effect of therapy for the two-way
ANOVA are presented in the text. The level of significance
was set to 0.05. The statistical analysis for effects of therapy
was adjusted for multiple testing according to Bonferroni-
Holm. All tests were performed using SAS software (ver-
sion 6.12; SAS Institute, Cary, North Carolina).
RESULTS
3H-Paclitaxel delivery. After 3H-paclitaxel delivery,
2.19 6 0.77% of the initial dose of 10 ml paclitaxel solution Ta
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(10 mmol/liter) was detected in the vessel wall and 1.80 6
1.21% was found in the adjacent myocardium. The relation
of these results to the weight of the samples showed an
activity of 43,286 6 16,386 dpm/mg tissue in the LAD and
496 6 287 dpm/mg tissue in the surrounding myocardium,
equaling 24.59 6 9.31 ng paclitaxel/mg tissue for the vessel
wall as opposed to only 0.28 6 0.16 ng/mg tissue in the
adjacent myocardium.
Intimal proliferation and endothelialization. In control
animals that underwent BD only, intimal proliferation at
day 7 was increased to 522 6 242 cells/mm2 and in animals
after local vehicle delivery to 483 6 325 cells/mm2. In
contrast, intimal SMC proliferation was markedly reduced
in paclitaxel-treated animals at day 7 (256 6 116 cells/mm2)
compared with solely balloon-dilated animals. Four and
eight weeks after intervention, intimal proliferation in all
groups was similar to baseline levels (p value for effects of
therapy: 0.0082, p value for effects of time: 0.0001, inter-
action: 0.0006). The exact data for all the different groups
are given in Figure 1. Immunostaining for endothelial cells
revealed no significant changes in endothelialization be-
tween paclitaxel-treated animals and control animals one,
four and eight weeks after intervention (therapy: p 5
0.0400, time: p 5 0.2680, interaction: p 5 0.3125).
Neointima formation and vessel size. The mean cross-
sectional intimal area in vessels from paclitaxel-treated
animals was constantly reduced compared with control
animals; however, this reduction was not significant. After
local paclitaxel delivery, the mean cross-sectional luminal
area was significantly enlarged, with a p value of 0.0020
(seven days after LDD: 1.153 6 0.651 mm2, preinterven-
tional baseline value: 0.492 6 0.274 mm2, balloon-dilated
animals: 0.654 6 0.258 mm2, animals after local vehicle
delivery: 0.672 6 0.189 mm2). Four and eight weeks after
LDD, the differences in mean luminal area were still present
(paclitaxel-treated animals: 0.787 6 0.116 mm2 and
0.754 6 0.165 mm2, solely balloon-dilated animals:
0.671 6 0.277 mm2 and 0.417 6 0.226 mm2). Correspond-
ing to these results, the extent of stenosis in paclitaxel-
treated animals was significantly reduced compared with
balloon-dilated control animals (p 5 0.0012, one, four and
eight weeks after intervention: 14.6 6 6.9%, 24.6 6 7.3%
and 20.5 6 5.3%, vs. 24.9 6 10.0%, 33.8 6 21.3% and 43.1
6 17.3%). A significant increase in the medial area was
observed in treated animals compared with balloon-dilated
controls (p 5 0.0001). The total vessel area, measured as the
area within the external elastic layer, was significantly larger
in paclitaxel-treated animals compared with balloon-dilated
control animals (p 5 0.0001) (Figs. 1 and 2). No significant
interaction between therapy and the different time points of
observation was found for the histomorphological results. A
detailed survey of all the results in the different study groups
is listed in Table 1.
Morphological results. Local paclitaxel delivery with the
double-balloon catheter resulted in only minimal additional
injury. No specific alterations such as local intimal damages,
disruptions in the internal elastic lamina, local medial
thickening or medial fracture could be detected. Serial
cutting revealed minimal intimal proliferation in areas
where the two balloons of the double-balloon catheter were
directly attached to the wall. This occurred in only 8 of 37
animals but could be clearly identified as a catheter-induced
vessel wall alteration. Local medial compression and thin-
ning with increased content of macrophages was detected in
five animals seven days after intervention with the double
balloon (three sham animals, two paclitaxel-treated ani-
mals). After local delivery of vehicle only, an increased
occurrence of thrombus formation was found, with four
mural or occlusive thrombi in 10 animals.
Tubulin staining showed an increase in the intensity of
Figure 1. Extent of intimal proliferation and the total vessel area in the different groups. Checked bars represent the preinterventional
control group, white bars stand for control animals that underwent BD only, hatched bars stand for sham animals that were treated with
vehicle and black bars stand for paclitaxel-treated animals.
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tubulin immunofluorescence, which was limited to the
luminal cell lining and subintimal area. The increase in
fluorescence intensity occurred in every cross-section of
paclitaxel-treated animals seven days after intervention.
However, this “fluorescence band” only showed in the area
of the vessel exposed to paclitaxel during intervention. Even
28 days after intervention, intensive fluorescence in the
luminal cell lining showed in about 40% to 50% of the
histologic sections from paclitaxel-treated animals. This
characteristic finding was not detected in any of the speci-
mens from the control animals at any time (compare with
Fig. 3). Specimens at the site of intense fluorescence were
then prepared for electron microscopy to further character-
ize paclitaxel-induced vessel wall alterations. Electron mi-
croscopy showed microtubules both in control animals and
in paclitaxel-treated animals. At very high magnification
(125,000 3), parallel microtubule bundles were detected in
vascular SMCs that had been exposed to local paclitaxel
delivery (Fig. 4). In contrast, no microtubule bundles were
found in control animals.
Contractile function. After induction of vascular contrac-
tion with KCl-enriched solution, the contraction forces of
both segments were measured. The contraction responses of
paclitaxel-treated vessel rings were quantified compared
with those of the respective controls. Incubation in 10
mmol/liter paclitaxel for 10 min led to a decrease in relative
contraction force to 22.8 6 1.4% compared with the control
segments. This effect was preserved after washing the vessel
segment in tyrode for 2 h (relative contraction force: 23.5 6
2.1%). After the incubation of vessel segments in 10
mmol/liter paclitaxel for 2 h and immediate measurement, a
further decrease in the relative contraction force (14.6 6
4.5%) was observed.
DISCUSSION
The results of this study indicate that local paclitaxel
delivery after experimental angioplasty leads to prolonged
enlargement in vessel size and a reduction in neointimal
stenosis. In addition to determining the amount of sub-
stance in the vessel wall, we were able to detect and
document some of the biological effects of paclitaxel on the
vasculature because of its unique mode of action.
Paclitaxel for LDD. Numerous pharmacological agents
with antiproliferative properties have been tested for the
potential to inhibit restenosis. Although initially promising,
clinical results have mostly been disappointing (18). Even
potent antimitotic compounds, such as methotrexate and
colchicine, fails to inhibit SMC proliferation and intimal
thickening in vivo (19,20). Although both paclitaxel and
compounds of the colchicine type inhibit cell division in the
M phase, opposite biological mechanisms are involved. In
contrast to antimicrotubule agents like colchicine, which
inhibit microtubule assembly, paclitaxel shifts the microtu-
bule equilibrium toward assembly, thereby interfering with
many functions of the cell such as proliferation, motility and
migration, intracellular transport and transmembrane sig-
naling (1–3,21). Moreover, activation processes associated
with microtubule depolymerization (such as activation of
protein kinases or release of transcription factors) are inhib-
ited by paclitaxel, which seems to be of important functional
relevance (22–24).
Paclitaxel has been shown to have an antiproliferative
effect on rat SMCs in vitro, as well as in vivo (7). In a
previous study, we could show that even after a short
single-dose application (10 min) on human SMC cell
culture, 10 mmol/liter paclitaxel exerted a sustained antipro-
liferative effect over a period of 14 days without showing
rebound or cytotoxic effects (6).
Toxicity of paclitaxel. A number of toxic effects are known
for paclitaxel in high-dose cancer therapy. The principal
side effects are hematological toxicity (neutropenia), neuro-
toxicity (peripheral neuropathy) and hypersensitivity reac-
Figure 2. Photomicrographs of cross sections showing the effect of
local paclitaxel delivery on vessel shape eight weeks after interven-
tion. A, Control animal after BD showing a characteristic eccentric
plaque formation with marked intimal thickening and lumen
reduction. B, Histological section 56 days after local paclitaxel
delivery showing the effects of paclitaxel on proliferation and vessel
enlargement. *Remains of the graphite-coated gold electrode that
had been loosely attached to the adventitia during electrostimula-
tion. Elastica van Gieson staining. Scale bars represent 300 mm.
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tions. Cardiac disturbances (mostly transient asymptomatic
bradycardia) have also been described, but all these side
effects occurred in patients undergoing high-dose chemo-
therapy for a malignant disease (3,25,26). The plasma levels
of paclitaxel in these patients are 100- to 1,000-fold higher
(over a longer time period) than plasma levels that would
result from a local infusion of 10 ml 10 mmol/liter paclitaxel.
With a lower limit of measurement of about 50 nmol/liter,
local paclitaxel delivery would not even result in measurable
plasma levels in humans (27).
Biological effects on the vessel wall and efficacy. In
previous studies with other locally delivered drugs, efforts
were made to determine the delivery efficiency by detecting
the drug (or marker substances) in the vessel wall (28–31).
In this study, 2.19% of the initially applied dose was
detected in the vessel wall after the delivery of 10 ml
radiolabeled paclitaxel (10 mmol/liter) with the double
balloon. A comparison of these results with other studies is
problematic due to different experimental approaches. It is
known, however, that the efficiency of LDD is generally
very low (32,33). At least in our own experience, the delivery
efficiency of the applied combination of lipophilic drug and
passive delivery system was 10- to 20-fold higher, when
compared with a previous study using a hydrophilic com-
pound (local delivery of low molecular weight heparin with
the porous balloon) (32).
Figure 4. Transmission electron microscopy of an intimal SMC
seven days after LDD showing a paclitaxel-induced microtubule
bundle. Microtubule bundles were not found in control animals.
Scale bar represents 0.2 mm.
Figure 3. Immunofluorescence micrographs after staining with a monoclonal anti-tubulin antibody. A, Adventitia of a control animal
seven days after angioplasty showing the specific staining of the cytoskeleton around the nucleus. B, Untreated control vessel after
electrostimulation only. C, Control animal seven days after BD showing heterogeneous staining within the neointima. D, Histologic
section seven days after local paclitaxel delivery showing an intensely stained “fluorescence band” at the luminal cell lining. Scale bars
represent 50 mm.
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The more important question, however, would be the
biological effects of this limited efficiency of LDD. The
specific action of paclitaxel on the cytoskeleton allows for a
unique feature: the detection of the drug action by staining
of tubulin and electron microscopy. In paclitaxel-treated
animals, tubulin staining showed an increase in fluorescence
intensity, indicating changes in microtubule assembly. This
gave reason for further investigations of the effects of
paclitaxel on the vessel wall by electron microscopy. In fact,
parallel microtubule bundles could be detected in SMCs
that had been exposed to local paclitaxel delivery. It has
been shown previously that these parallelly orientated mi-
crotubule bundles are a typical paclitaxel-induced modifica-
tion in microtubule assembly (34,35). In control animals, no
changes in the cytoskeleton were found at any time point.
The biological significance of these structural changes
was assessed quantitatively in the different intervention
groups. The morphological observation of an altered cy-
toskeleton within neointimal SMCs agrees well with the
reduced intimal proliferation at an early stage after inter-
vention in paclitaxel-treated animals compared with
balloon-dilated control animals. In this study, reendotheli-
alization after intervention did not differ significantly be-
tween paclitaxel-treated animals and control animals. In a
previous study, we showed that higher concentrations of
paclitaxel are needed to inhibit endothelial cell growth and
SMC growth similarly (6). Because an intact endothelium is
regarded as an important regulator for proliferation control,
it is of great importance that these cell culture findings are
preserved in the in vivo situation (36). The reduced neoin-
tima formation and extent of stenosis can simply be ex-
plained by the reduced intimal SMC proliferation after
paclitaxel delivery. However, stenosis is not only caused by
neointimal proliferation, but also by the reduction of resid-
ual lumen (37). After local paclitaxel delivery, the luminal
area, medial area and total vessel area were consistently
larger than in control animals. The reason for the observed
medial hypertrophy in paclitaxel-treated animals remains
unclear; however, this effect has also been described for
other compounds (38). Theoretically, the effects on lumen
and total vessel area might also have been caused by an
additional dilation effect of the applied fluid between the
two balloons of the double-balloon catheter. Therefore, the
outer diameter of the vessel was carefully measured in situ
and the carotid artery was only slightly mobilized during
operation. With an infusion pressure of 0.1 to 0.5 atm, there
was no additional dilation caused by the double balloon. In
order to substantiate this observation, additional control
animals were treated with local delivery of vehicle only, and
the results in this study group also favor a drug effect and
not an additional mechanical effect of the delivery system
(compare with Table 1). Furthermore, vessel enlargement
was also observed after a cytoskeleton-affecting therapy with
other compounds, and the vasocontraction experiments of
this study clearly indicate an effect caused by paclitaxel.
Thus, the effects of paclitaxel on proliferation and vessel
enlargement contribute both to a preservation of vessel
shape and are likely to be caused by a structural alteration of
the cytoskeleton. Paclitaxel does not act by a receptor-
mediated mechanism and the highly lipophilic character of
the drug promotes its cellular uptake. Additionally, the
cytoskeleton is a well-preserved structure in evolution.
Bearing in mind the pitfalls of transferring animal data into
the clinical setting, this might be an advantage of a
cytoskeleton-targeting therapy. Thus, local paclitaxel ther-
apy with the double-balloon catheter might be a promising
approach for the reduction of restenosis after percutaneous
transluminal coronary angioplasty.
Study limitations. Local drug delivery in coronary arteries
for a period of 10 min would require a device that allows for
a residual blood stream through a perfusion lumen. A
modified double-balloon catheter with a perfusion lumen is
being developed. Even with the closed-chamber design of
the double balloon, most of the delivered agent reaches the
bloodstream, especially in coronaries with their side
branches, and might cause adverse systemic side effects.
Therefore, larger series of animal experiments as well as
studies investigating local and systemic effects of paclitaxel
in coronary arteries are desirable.
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